Americans may end up paying more for their medicines as well as facing shortages of drugs they need. So it's possible there ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...